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Abstract
Objectives: As of December, 1st, 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, resulted in
more than 1 472 917 deaths worldwide and death toll is still increasing exponentially. Many COVID-19 infected
people are asymptomatic or experience moderate symptoms and recover without medical intervention. However,
older people and those with comorbid hypertension, diabetes, obesity, or heart disease are at higher risk of
mortality. Because current therapeutic options for COVID-19 patients are limited specifically for this elderly
population at risk, Biophytis is developing BIO101 (20-hydroxyecdysone, a Mas receptor activator) as a new
treatment option for managing patients with SARS-CoV-2 infection at the severe stage.
The angiotensin converting enzyme 2 (ACE2) serves as a receptor for SARS-CoV-2. Interaction between ACE2 and
SARS-CoV2 spike protein seems to alter the function of ACE2, a key player in the renin-angiotensin system (RAS).
The clinical picture of COVID-19 includes acute respiratory distress syndrome (ARDS), cardiomyopathy, multiorgan
dysfunction and shock, all of which might result from an imbalance of the RAS. We propose that RAS balance could
be restored in COVID-19 patients through MasR activation downstream of ACE2 activity, with 20-hydroxyecdysone
(BIO101) a non-peptidic Mas receptor (MasR) activator. Indeed, MasR activation by 20-hydroxyecdysone harbours
anti-inflammatory, anti-thrombotic, and anti-fibrotic properties. BIO101, a 97% pharmaceutical grade 20-
hydroxyecdysone could then offer a new therapeutic option by improving the respiratory function and ultimately
promoting survival in COVID-19 patients that develop severe forms of this devastating disease. Therefore, the
objective of this COVA study is to evaluate the safety and efficacy of BIO101, whose active principle is 20-
hydroxyecdysone, in COVID-19 patients with severe pneumonia.
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Trial design: Randomized, double-blind, placebo-controlled, multi-centre, group sequential and adaptive which will
be conducted in 2 parts.
Part 1:
Ascertain the safety and tolerability of BIO101 and obtain preliminary indication of the activity of BIO101, in
preventing respiratory deterioration in the target population
Part 2:
Re-assessment of the sample size needed for the confirmatory part 2 and confirmation of the effect of BIO101
observed in part 1 in the target population.
The study is designed as group sequential to allow an efficient run-through, from obtaining an early indication of
activity to a final confirmation. And adaptive – to allow accumulation of early data and adapt sample size in part 2
in order to inform the final design of the confirmatory part of the trial.
Participants: Inclusion criteria
1. Age: 45 and above
2. A confirmed diagnosis of COVID-19 infection, within the last 14 days, prior to randomization, as determined
by PCR or other approved commercial or public health assay, in a specimen as specified by the test used.
3. Hospitalized, in observation or planned to be hospitalized due to COVID-19 infection symptoms with
anticipated hospitalization duration ≥3 days
4. With evidence of pneumonia based on all of the following:
a. Clinical findings on a physical examination
b. Respiratory symptoms developed within the past 7 days
5. With evidence of respiratory decompensation that started not more than 4 days before start of study
medication and present at screening, meeting one of the following criteria, as assessed by healthcare staff:
a. Tachypnea: ≥25 breaths per minute
b. Arterial oxygen saturation ≤92%
c. A special note should be made if there is suspicion of COVID-19-related myocarditis or pericarditis, as
the presence of these is a stratification criterion
6. Without a significant deterioration in liver function tests:
a. ALT and AST ≤ 5x upper limit of normal (ULN)
b. Gamma-glutamyl transferase (GGT) ≤ 5x ULN
c. Total bilirubin ≤ 5×ULN
7. Willing to participate and able to sign an informed consent form (ICF). Or, when relevant, a legally authorized
representative (LAR) might sign the ICF on behalf of the study participant
8. Female participants should be: at least 5 years post-menopausal (i.e., persistent amenorrhea 5 years in the
absence of an alternative medical cause) or surgically sterile; OR
a. Have a negative urine pregnancy test at screening
b. Be willing to use a contraceptive method as outlined in inclusion criterion 9 from screening to 30
days after last dose.
9. Male participants who are sexually active with a female partner must agree to the use of an effective method
of birth control throughout the study and until 3 months after the last administration of the investigational
product.
(Continued on next page)
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(Note: medically acceptable methods of contraception that may be used by the participant and/or partner include
combined oral contraceptive, contraceptive vaginal ring, contraceptive injection, intrauterine device, etonogestrel implant,
each supplemented with a condom, as well as sterilization and vasectomy).
10. Female participants who are lactating must agree not to breastfeed during the study and up to 14 days after
the intervention.
11. Male participants must agree not to donate sperm for the purpose of reproduction throughout the study and
until 3 months after the last administration of the investigational product.
12. For France only: Being affiliated with a European Social Security.
Exclusion criteria
1. Not needing or not willing to remain in a healthcare facility during the study
2. Moribund condition (death likely in days) or not expected to survive for >7 days – due to other and non-
COVID-19 related conditions
3. Participant on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane
oxygenation (ECMO), or high-flow Oxygen (delivery of oxygen at a flow of ≥16 L/min.).
4. Participant is not able to take medications by mouth (as capsules or as a powder, mixed in water).
5. Disallowed concomitant medication: Consumption of any herbal products containing 20-hydroxyecdysone
and derived from Leuzea carthamoides; Cyanotis vaga or Cyanotis arachnoidea is not allowed (e.g. performance
enhancing agents).
6. Any known hypersensitivity to any of the ingredients, or excipients of the study medication, BIO101.
7. Renal disease requiring dialysis, or known renal insufficiency (eGFR≤30 mL/min/1.73 m2, based on Cockcroft &
Gault formula).
8. In France only:
a. Non-affiliation to compulsory French social security scheme (beneficiary or right-holder).
b. Being under tutelage or legal guardianship.
Participants will be recruited from approximately 30 clinical centres in Belgium, France, the UK, USA and Brazil.
Maximum patients’ participation in the study will last 28 days. Follow-up of participants discharged from hospital
will be performed through post-intervention phone calls at 14 (± 2) and 60 (± 4) days.
Intervention and comparator: Two treatment arms will be tested in this study: interventional arm 350 mg b.i.d. of
BIO101 (AP 20-hydroxyecdysone) and placebo comparator arm 350 mg b.i.d of placebo. Administration of daily
dose is the same throughout the whole treatment period. Participants will receive the study medication while
hospitalized for up to 28 days or until a clinical endpoint is reached (i.e., ‘negative’ or ‘positive’ event). Participants
who are officially discharged from hospital care will no longer receive study medication.
Main outcomes: Primary study endpoint:
The proportion of participants with ‘negative’ events up to 28 days.
‘Negative’ events are defined as respiratory deterioration and all-cause mortality. For the purpose of this study,
respiratory deterioration will be defined as any of the following:
– Requiring mechanical ventilation (including cases that will not be intubated due to resource restrictions and
triage).
– Requiring extracorporeal membrane oxygenation (ECMO).
– Requiring high-flow oxygen defined as delivery of oxygen at a flow of ≥16 L/min.
(Continued on next page)
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Only if the primary endpoint is significant at the primary final analysis the following
Key secondary endpoints will be tested in that order:
– Proportion of participants with events of respiratory failure at Day 28
– Proportion of participants with ‘positive’ events at Day 28.
– Proportion of participants with events of all-cause mortality at Day 28
A ‘positive’ event is defined as the official discharge from hospital care by the department due to improvement in
participant condition.
Secondary and exploratory endpoints:
In addition, a variety of functional measures and biomarkers (including the SpO2 / FiO2 ratio, viral load and markers
related to inflammation, muscles, tissue and the RAS / MAS pathways) will also be collected.
Randomization: Randomization is performed using an IBM clinical development IWRS system during the baseline
visit. Block-permuted randomization will be used to assign eligible participants in a 1:1 ratio.
– In part 1, randomization will be stratified by RAS pathway modulator use (yes/no) and co-morbidities (none vs.
1 and above).
– In Part 2, randomization will be stratified by centre, gender, RAS pathway modulator use (yes/no), co-
morbidities (none vs. 1 and above), receiving Continuous Positive Airway Pressure/Bi-level Positive Airway
Pressure (CPAP/BiPAP) at study entry (Yes/No) and suspicion of COVID-19 related myocarditis or pericarditis
(present or not).
Blinding (masking): Participants, caregivers, and the study team assessing the outcomes are blinded to group
assignment. All therapeutic units (TU), BIO101 b.i.d. or placebo b.i.d., cannot be distinguished in compliance with
the double-blind process. An independent data-monitoring committee (DMC) will conduct 2 interim analyses. A
first one based on the data from part 1 and a second from the data from parts 1 and 2. The first will inform about
BIO101 safety, to allow the start of recruitment into part 2 followed by an analysis of the efficacy data, to obtain an
indication of activity. The second interim analysis will inform about the sample size that will be required for part 2,
in order to achieve adequate statistical power.
Numbers to be randomised (sample size)
Number of participants randomized: up to 465, in total
– Part 1: 50 (to obtain the proof of concept in COVID-19 patients).
– Part 2: 310, potentially increased by 50% (up to 465, based on interim analysis 2) (to confirm the effects of
BIO101 observed in part 1).
Trial Status: The current protocol Version is V 10.0, dated on 24.09.2020. The recruitment that started on
September 1st 2020 is ongoing and is anticipated to finish for the whole study by March2021.
Trial registration: The trial was registered before trial start in trial registries: EudraCT, No. 2020-001498-63,
registered May 18, 2020; and Clinicaltrials.gov, identifier NCT04472728, registered July 15, 2020.
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter
serves as a summary of the key elements of the full protocol.
Keywords: COVID-19, SARS-CoV2, randomised controlled trial, Renin Angiotensin System, Mas receptor, angiotensin
converting enzyme-2, 20-hydroxyecdysone, BIO101, Inflammation, Acute respiratory Distress Syndrome
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13063-020-04998-5.
Additional file 1. Full Protocol
Acknowledgements
The contribution of Dr L.N. Dinan for critical reading of the manuscript and
language improvement is acknowledged.
Authors’ contributions
MLa, SC, RL and PJD contributed to the scientific rationale of BIO101
mechanism of action for the study. MC, CT, WD, AA, CMP and SA, were
Dioh et al. Trials           (2021) 22:42 Page 4 of 5
responsible for the study design, preparation and setting up of the study
protocol; MC, CT, AA, WD, and SA were responsible for the study
organisation and obtaining approvals from ethics committee and competent
authorities; CMP is the Principal Investigator of this study; CMP, LAH, ML,
GBN and TW are country investigators of this study; SC, SA, CT, WD, AA and
MC drafted the manuscript; MC, CTO, CMP, PJD, WD, JM, RL, SA, AA and SV
revised the manuscript for important intellectual content. All authors
approved the final version of the manuscript and contributed to conducting
the trial.
Funding
This study is sponsored and funded by BIOPHYTIS SA, 14 Avenue de l’Opéra,
75001 Paris France, a private company developing BIO101. The funding does
and will not have an influence on the design of the study, collection,
analysis and interpretation of data and in writing the manuscript besides
financial support.
Availability of data and materials
The datasets generated and/or analysed during the current study are not
publicly available due to the fact that they are the private properties of
BIOPHYTIS SA.
Ethics approval and consent to participate
The current clinical protocol version 10 was approved by the French and
Belgium ethic committees. The submission to EC in Brazil, UK and US is
ongoing.
Belgium: Ethics committee Universitair Ziekenhuis Antwerpen Ethisch Comité
Ethical approval number: 2020-001498-63/SM003. Date of approval: October,
2nd, 2020.
France Ethics committee Le Comité de Protection des Personnes (CPP) Ouest
V Ethical approval number: 20/028-1 COVID (CNRIPH ref: 20.04.01.63336), date
of approval: December, 1st , 2020.
We certify that this trial has received approvals from the appropriate ethical
committees as described above. Written informed consent will be obtained




We declare non-competing interest that all authors apart from CMP, LAH,
ML, TW and GBN are employees of BIOPHYTIS SA. We believe, however, that
the company’s potential commercial interests had no impact on the scien-
tific rationale or conduct of the trial.
CMP, LAH, ML, TW and GBN are members of the COVA steering committee
and country clinical investigators and declare no-competing interests.
Author details
1Biophytis SA, Sorbonne Université – BC9, 4 place Jussieu, 75005 Paris,
France. 2Biophytis, Inc, 210 Broadway, Suite #201, Cambridge, MA 02139,
USA. 3Service de Pneumologie, Médecine Intensive et Réanimation - R3S
(SPMIR-R3S), Hôpital Pitié-Salpêtrière – APHP, Paris, France. 4Universidade de
São Paulo Instituto do Coração, São Paulo, SP, Brasil. 5General Hospital
Sint-Maarten, Mechelen, Belgium. 6Oakland University William Beaumont
School of Medicine, Royal Oak, MI, USA. 7Queen Elizabeth Hospital
Birmingham, Birmingham B15 2GW, UK. 8Sorbonne Université, CNRS - Institut
de Biologie Paris Seine (B2A), 75005 Paris, France. 9Sorbonne Université, CNRS
- Institut de Biologie Paris Seine (BIOSIPE), 75005 Paris, France.
Received: 17 December 2020 Accepted: 23 December 2020
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Dioh et al. Trials           (2021) 22:42 Page 5 of 5
